biosimilars

Why pharmacists are concerned about the safety of biosimilarsPharmacists and other healthcare professionals are looking to the FDA for more guidance on biosimilars and interchangeability with their reference products.
Biosimilars for cancer treatment on the U.S. horizonCancer treatments are expected to dominate much of the first wave of biosimilars in the U.S. This Q&A discussion looks at some of the questions pharmacists have about use of biosimilars in cancer treatment.
Biosimilar: Coming to a pharmacy near youBiosimilars are the future of pharmacy. When they hit community pharmacy, issues that have been important in specialty settings are going to explode.
Biosimilar drugs appear comparable to brand-name counterpartsSystematic review provides comprehensive first look at TNF-alpha biosimilar treatments.
New bill aims to support generic, biosimilar drug competitionThe CREATES Act came about because some pharmaceutical manufacturers are misusing the REMS program to prevent generic drug development.
Survey finds stakeholders lack understanding of biosimilarsIt is important to look at how the introduction of biosimilars in the United States may affect your business and your stakeholders and plan for those changes accordingly, according to a new report.
Biosimilars uptake may lag for cancer patients, physiciansBiosimilars will have a significant impact on cancer treatment, with the potential to drive cost savings, but will patients and providers be accepting?
Arizona passes pharmacy biosimilar lawArizona recently joined around 20 other states by passing a law allowing pharmacists to substitute certain interchangeable biosimilar drugs for brand name drugs.
The biosimilar balance: More options, lower costsThe fly in the ointment: CMS' current plan for HCPCS codes is a real buzz kill.
Predictions for the future of high-cost specialty drugsIMS Health expert predicts future drug spending trends and ways to curb rising costs at the AMCP 2016 conference.